openPR Logo
Press release

Sacituzumab Govitecan, A Kind of ADC Drug Against Triple-Negative Breast Cancer

01-28-2021 12:36 PM CET | Fashion, Lifestyle, Trends

Press release from: Biochempeg Scientific Inc.

Sacituzumab Govitecan, A Kind of ADC Drug Against

On April 22, the FDA approved sacituzumab govitecan for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. It is a next generation antibody-drug conjugate designed by Immunomedics Inc.

Sacituzumab govitecan is the first antibody-drug conjugate approved by the FDA specifically for relapsed or refractory metastatic triple-negative metastatic breast cancer. It is also the first FDA-approved anti–Trop-2 antibody-drug conjugate. The agent is a Trop-2–directed antibody and topoisomerase inhibitor drug conjugate.

Metastatic triple-negative breast cancer is an aggressive form of breast cancer with limited treatment options. Chemotherapy has been the mainstay of treatment for triple-negative breast cancer. The approval of sacituzumab govitecan represents a new targeted therapy for patients living with this aggressive malignancy.

IMMU-132-01

The FDA approved sacituzumab govitecan based on the results of the phase II IMMU-132-01 clinical trial of 108 patients with metastatic triple-negative breast cancer who had received a range of 2 to 10 prior treatments for metastatic disease. Patients received sacituzumab govitecan at 10 mg/kg intravenously on days 1 and 8 every 21 days. Tumor imaging was obtained every 8 weeks, and patients were treated until disease progression or intolerance to therapy.

The efficacy of sacituzumab govitecan was based on the overall response rate. The overall response rate was 33.3% (95% confidence interval [CI] = 24.6%–43.1%), with a median duration of response of 7.7 months (95% CI = 4.9–10.8). Of the patients with a response to sacituzumab govitecan, 55.6% maintained their response for 6 or more months and 16.7% maintained their response for 12 or more months.

The most common reported side effects (occurring in 25% or more of patients) were nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, decreased appetite, rash, and abdominal pain. The most common grade 3 or 4 adverse events (occurring in more than 5% of patients) were neutropenia, white blood cell count decreased, anemia, hypophosphatemia, diarrhea, fatigue, nausea, and vomiting.

Two percent of patients discontinued treatment due to adverse events. There were no deaths related to treatment, and no severe cases of neuropathy or interstitial lung disease.

The prescribing information for sacituzumab govitecan includes a Boxed Warning to advise health-care professionals and patients about the risk of severe neutropenia and severe diarrhea.

Continued approval of sacituzumab govitecan may be contingent upon verification of clinical benefit in the confirmatory phase III ASCENT study, which was recently halted by the independent data safety monitoring committee for compelling evidence of efficacy across multiple endpoints.

The recommended sacituzumab govitecan dose is 10 mg/kg administered by intravenous infusion administered on days 1 and 8 every 21 days until disease progression or unacceptable toxicity.

Biochempeg, a leading PEG supplier can provide GMP standard PEG derivatives and ADC linkers with small quantity or bulk orders to customers all over the world based on their special quality requirements. It provides 2-((Azido-PEG8-carbamoyl)methoxy)acetic acid (CAS NO.: 846549-37-9), which is a fragment of IMMU-132.

Company: Biochempeg Scientific Inc.
Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA
Email: sales@biochempeg.com
Website: https://www.biochempeg.com

Biochempeg is a biotechnology-oriented company in Watertown, Massachusetts. We are dedicated to manufacturing and supplying high purity polyethylene glycol (PEG) derivatives and reagents, monodisperse PEG, Click Chemistry reagents, PEGylation services and custom PEG derivative synthesis to clients worldwide. These PEG reagents have been widely used in bioconjugation, antibody-drug conjugates (ADCs) therapeutic, drug delivery and diagnostics field.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sacituzumab Govitecan, A Kind of ADC Drug Against Triple-Negative Breast Cancer here

News-ID: 2232057 • Views: 353

More Releases from Biochempeg Scientific Inc.

Sacituzumab Govitecan Approval for Advanced or Metastatic Urothelial Cancer
On April 13, 2021, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Sacituzumab Govitecan (from Gilead Sciences) for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. Sacituzumab govitecan is a first-in-class Trop-2-directed antibody-drug conjugated to a topoisomerase I inhibitor (SN-38). Trop-2 receptor, a protein frequently expressed in multiple types
The Application of Click Chemistry In Life Sciences
Click chemistry has come into its own in a wide range of life science applications and opens up opportunities that lie between chemistry, biology and material science. Twenty years ago, soon-to-be Nobel laureate Barry Sharpless and co-workers began to promote the idea of designing reactions that would simply ‘click’, that is, proceed efficiently and selectively under mild reaction conditions. Initially, these chemists were mainly thinking of clicking together existing organic molecules to accelerate the discovery of new compounds with useful properties. But since then, our ability to customise and manufacture a wide range of biological entities, from antibodies to cells, has grown immeasurably, and click chemistry has also come into its own in a wide range of life science applications. What is click chemistry? Click chemistry is modular, wide in scope, gives very high reaction yields and generates only harmless by-products. Ideally insensitive to water and oxygen, the reaction conditions are benign, and the product requires little downstream purification. This would have excluded classic reactions like the Huisgen cycloaddition of an alkyne and an azide, which is useful for linking molecules, as traditionally this reaction requires refluxing in an organic solvent at 100˚C and still produces a mixture of isomer products. However, the addition of copper as a catalyst transforms the reaction into a prime example of click chemistry, by speeding up the reaction at lower temperature and favouring the formation of only one product.  Yet, even trace amounts of copper can be difficult to remove and harmful to cells. A copper-free click reaction was created by adding ring strains - akin to ‘loaded springs’ - to the click reactants. Releasing such strain becomes the driving force for the reaction, which readily proceeds at room temperature and without the metal catalyst. With progress in catalysts and the utilisation of ring strains, many classic chemical reactions have been reinvented as click chemistry and can now be carried out at ambient temperatures and under conditions that are harmless to living organisms and biological molecules. These attributes make click chemistry particularly appealing for bioconjugation, where biocompatible, highly specific and non-toxic chemical strategies are required to join together two or more molecules, one of which is a biomolecule. Only a ‘click’ away Similar to a lock and key system, click moieties are designed to react only with their click counterparts without cross-reaction with other functional groups. As they are small as well as water soluble, clickable reagents are also easily taken up by cells and can even cross the blood-brain barrier. Clickable components can be incorporated into the building blocks of cells, proteins and nucleic acids via biosynthesis or chemical modifications.  For example, during protein biosynthesis, cells may be tricked into incorporating an unnatural amino acid containing a click-ready group into the protein sequence, by a combination of specially engineered tRNA, ribosome and parallel genetic codes.  Alternatively, one can directly modify features of biomolecules, such as the glycan chains on antibodies and on the cell surface, to functionalise them with click-ready groups. Thereafter, these click moiety-containing biologics can be coupled to various other probes such as fluorescent labels, small-molecule drugs, carbohydrates, DNAs or RNAs, and proteins.  The good news for non-chemists is that there are already a number of reagent companies that sell ready-made click building blocks with easy-to-follow recipes, so they can be used in the desired applications straightaway. This provides a solution for carrying out simple chemistry on bench, without having to access Schlenk line, fume hood, and chromatography in a chemical laboratory. Click chemistry in life science applications Click chemistry is already widely used in pharmaceutical and life science applications and increasingly prompting large commercial deals. Drug discovery has been boosted by click chemistry, as not only the resulting chemical linkages (such as the triazole ring) are highly useful in medicinal chemistry, but also new and potentially more active compounds can be formed by clicking existing compounds together. This is seen in fragment-based drug screening and PROTAC, a targeted protein degradation drug platform, which is considered as the next hot drug development area. In the nucleic acid sequencing arena, ClickSeq, a click chemistry-based method for RNA sequencing has proven to be more robust and less error-prone than the enzymatic ligation commonly used to link sequencing adaptors during the creation of libraries for next-generation Illumina sequencing. Click chemistry also enables the coupling of antibodies and cytotoxic drugs to produce site-specific and stable antibody-drug conjugates (ADCs).  Biochempeg is especially good at click chemistry reagents which now widely used on biomolecular probes, two-dimensional gel electrophoresis separation, modification of peptide function with triazoles and natural products, and pharmaceuticals, nanotechnology, Biomaterials, etc. Company: Biochempeg Scientific Inc. Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA Email: sales@biochempeg.com Website: https://www.biochempeg.com Biochempeg is a biotechnology-oriented company in Watertown, Massachusetts. We are dedicated to manufacturing and supplying high purity polyethylene glycol (PEG) derivatives and
New Nanoparticle Can Kill Cancer Cells Efficiently And Selectively
Ludwig-Maximilians-Universitaet (LMU) in Munich researchers have developed a novel type of nanoparticle that efficiently and selectively kills cancer cells, thus opening up new therapeutic options for the treatment of tumors. Many chemotherapeutic agents used to treat cancers are associated with side-effects of varying severity, because they are toxic to normal cells as well as malignant tumors. This has motivated the search for effective alternatives to the synthetic pharmaceuticals with which most
Immunotherapy, The Most Prominent Topic In Skin Cancer Research
A report published on May, 21, 2019 highlights the different research areas in the field of skin cancer, showing that immunotherapy is the most prominent topic and reveals the countries that are driving this research. The study, “Melanoma Research Insights: Impact, Trends, Opportunities”, released during Skin Cancer Awareness Month by information analytics business Elsevier, maps and analyses academic research on melanoma globally between 2013-2018. Findings in the report highlight that melanoma

All 5 Releases


More Releases for PEG

PEG-12 Dimethicone Market: Competitive Dynamics & Global Outlook 2025
LP INFORMATION recently released a research report on the PEG-12 Dimethicone market analysis, which studies the PEG-12 Dimethicone's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global “PEG-12 Dimethicone Market 2020-2025” Research Report categorizes the global PEG-12 Dimethicone market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth
PEG-10 Dimethicone Market: Competitive Dynamics & Global Outlook 2025
LP INFORMATION recently released a research report on the PEG-10 Dimethicone market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global PEG-10 Dimethiconemarket by key players, product type, applications and regions,etc. The main objective of this market research is to help the readers understand the structure of PEG-10 Dimethiconemarket, market definition, overview, industry opportunities and trends, investment
Application of PEG In Click Chemistry
Polyethylene glycol (PEG) is a biocompatible, synthetic, hydrophilic polyether compound that has many applications, mostly in the medical industry, but also in the chemical and industrial sectors. The synthesis of PEG is done by polymerizing ethylene oxide, the main ingredient in antifreeze, using a ring-opening technique, which allows for PEGs of a range of molecular weights and molecular weight distributions to be constructed. This range in weights is what makes
What Are PEG Linkers?
Hydrophilic poly(ethylene glycol) or PEG-linkers are particularly attractive as a linker for conjugation. Water solubility, lack of toxicity; low immunogenicity and well defined chain lengths and molecular weights are specific characteristics of PEG moieties relevant to pharmaceutical applications. Hydrophilic linkers The link between the antibody and the cytotoxic agent plays a critical role in development of antibody-drug conjugates. The nature of the linker can significantly affect the potency, selectivity, and the pharmacokinetics of
Biochempeg developed a series of PEG compounds used for Semaglutide
Type 2 diabetes is the most common form of diabetes. Semaglutide is an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. It reduces blood sugar via increasing the production of insulin. Biochempeg has developed and can supply some key intermediates of Semaglutide. Semaglutide(trade names: Rybelsus,Ozempic) is a medication for the treatment of type 2 diabetes. It was discovered in 2012, by a team of researchers
Global PEG Stearate Market Huge Growth Opportunity between 2020-2025
LP INFORMATION recently released a research report on the PEG Stearate market analysis, which studies the PEG Stearate's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global "PEG Stearate Market 2020-2025" Research Report categorizes the global PEG Stearate market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth